Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Drug Profile

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05; SUNOSI

Latest Information Update: 20 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK Holdings
  • Developer Jazz Pharmaceuticals plc; SK biopharmaceuticals
  • Class Carbamates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypersomnia
  • Discontinued Depressive disorders

Most Recent Events

  • 03 Jul 2019 Launched for Hypersomnia in USA (PO)
  • 25 Jun 2019 Jazz Pharmaceutical plans to launch Solriamfetol in USA, in early July 2019
  • 17 Jun 2019 Solriamfetol receives Schedule IV medicine designation from the US Drug Enforcement Agency (DEA) for daytime sleepiness associated with narcolepsy or obstructive sleep apnea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top